Study on SARS-CoV Fusion Protein for Diagnosis and Vaccine
Author Information
Author(s): Mu Feng, Niu Dongsheng, Mu Jingsong, He Bo, Han Weiguo, Fan Baoxing, Huang Shengyong, Qiu Yan, You Bo, Chen Weijun
Primary Institution: Beijing Institute of Genomics, Chinese Academy of Sciences
Hypothesis
The truncated S-N fusion protein of SARS-CoV can serve as a diagnostic antigen and a vaccine candidate.
Conclusion
The truncated S-N fusion protein is a suitable immunodiagnostic antigen and vaccine candidate.
Supporting Evidence
- The diagnostic sensitivity of the truncated S-N fusion protein was > 99%.
- Immunized mice showed high titers of antibodies against SARS-CoV.
- The fusion protein induced a specific T-cell response in mice.
Takeaway
Scientists created a new protein from the SARS virus that can help diagnose the disease and might also be used to make a vaccine.
Methodology
The study involved cloning and expressing the truncated S-N fusion protein in E. coli, followed by immunological assays in mice and serological tests with human sera.
Potential Biases
Potential bias in the selection of sera from SARS patients and healthy controls.
Limitations
The study primarily focused on mouse models, which may not fully represent human responses.
Participant Demographics
460 SARS convalescent sera and 650 healthy blood donor sera were used.
Statistical Information
P-Value
0.0084
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website